JSM Women's Health

Geographic Distribution of Cervical Cancer in California: A Population Based Study

Research Article | Open Access Volume 1 | Issue 1 |

  • 1. School of Public Health, Loma Linda University, USA
  • 2. Analysis and Technologies Laboratory, Loma Linda University, USA
  • 3. Department of Preventive Medicine, Loma Linda University, USA
  • 4. School of Public Health, Loma Linda University, USA
+ Show More - Show Less
Corresponding Authors
John W. Morgan, School of Public Health, Loma Linda University, School of Public Health, 24951 North Circle Drive, Loma Linda, Regions 4, 5, 7 and 10 of the Cancer Registry of Greater California CA, 92350, USA, Tel: 909-558-6181;

Cervical cancer was a leading cause of cancer death among American women before screening began in the 1940s [1]. Approximately 12,900 American women will be diagnosed with cervical cancer during 2015, and 4,100 will succumb to this disease during the same year [2]. During 2000, California showed the second highest incidence rate for cervical cancer in the US [3], with 2,663 deaths from cervical cancers among residents in California during 2006-2011 [6]. Overwhelmingly, cervical cancers arise from premalignant dysplasia, which can progress to cancer. Since the 1950s [6], the Papanicolaou (Pap) test has been used for detection of premalignant cervical dysplasia and cancer [3,6,7] and to improve survival through early treatment [8,9]. The majority of cervical cancers in the US are epidermoid carcinomas (67%), with the remainder classified as a deno carcinomas (27%) or other histologies that include specified and unspecified carcinomas or sarcomas [10]. Approximately 99 percent of cervical cancers result, in part from one of 13 human papilloma virus (HPV) subtypes [11], with two vaccines available for the most common subtypes [12]. In spite of the effectiveness of HPV vaccination, the value of Pap testing for detection of premalignant cervical dysplasia and early cervical cancer will extend into the foreseeable future [13-15]

Race and ethnicity are frequently used as predictors of latestage cervical cancer [16,17], while researchers have suggested that this effect results substantially from low SES [16,18,19]. Low SES, which is theoretically modifiable, predicts inadequate Pap testing [20-22], higher incidence rates [20,23-26] and later stage at diagnosis [8,10,19] for cervical cancer, with these outcomes predicted by large area geographic units. Intensified targeting of screening to high risk regions of California may improve cervical cancer control and prevention

Various researchers have used community SES indices ranging from single variable measures to those using multiple dimensions including income [20], education [51], poverty [21,51,52] and other social or economic characteristics. Three indices measuring ecologic SES quintiles at the census block group (BG) level have been developed for use in the diverse California population. Among these, the prototype multidimensional BG level SES quintile index was based on a principal component regression model using seven, Year 1990 Census long form variables that included education, median income, percentage living below the poverty level, median rent, median house value, proportion with a blue-collar job and proportion in the workforce without a job that were older than age 16 years [27]. Similar methods used block group data from the Year 2000 Census, updating the original index for 1996-2005. The most current SES index, applicable to years 2006-2011, was derived using the same component variables and methods as the earlier indices, used Year 2010 Census BGs and data from the American Community Survey [28].

The California Cancer Registry (CCR), operated continuously since 1988, consists of the three most populated Surveillance Epidemiology and End Results (SEER) program registries and includes data for malignant neoplasms diagnosed among more than 37 million California residents [10]. Variables available in the CCR include age, sex, community SES quintiles, demographic information, cancer anatomic site and histology, behavior and Year 2010 Census BG of residence at diagnosis


This study sought to use epidemiologic methods and geographic information systems (GIS) tools to determine whether sub-county aggregations of cervical cancers existed in California and to map geographic areas depicting unique cervical cancer occurrence. Additionally, this research sought to map subcounty areas of California exhibiting unique SES patterns and to map and test spatial cross-correlations between aggregations of unique cervical cancer occurrence and SES, seeking to enhance control and prevention strategies


This population-based, cross-sectional study identified geographic aggregations of cervical cancer occurrence measured at the Year 2010 Census BG level in California for 2006-2011 using Statistical Analysis Software (SAS) version 9.4 [29] and Arc GIS version 10.3 [30]. Variables used in this analysis included age at diagnosis, year of diagnosis (2006-2011), histology for invasive cervical epidermoid carcinoma (M-8050-8052, 8070- 8076, 8082-8084) and adeno carcinomas (M-8140, 8144-8145, 8147, 8200, 8210, 8240, 8245, 8246, 8255, 8260, 8263, 8310, 8323, 8380, 8384, 8430, 8441, 8460-8461, 8480, 8482, 8490, 8501, 8523, 8542, 8560, 8570, 8574) [31], an ecologic SES quintile index (1-lowest, 5-highest) [28] for each California, Year 2010 Census BG, regardless of other demographic characteristics. Age-, race/ethnicity- and marital status-crude incident ratios (IR) for cervical cancer were computed as the ratio of observed cases, divided by the expected count for each of the 23,212 Year 2010 Census BGs in California. The expected number for each BG was computed using indirect standardization [32] by applying the statewide average risk to the number of women residents, age 20 years or older in each California Year 2010 Census BG.

BG-level IRs was mapped using a spatial smoothing method [42,43] to improve statistical reliability for sparsely populated sub-county areas. IR values were estimated for individual points that were spaced every two kilometers forming a grid that encompassed the entire state. This adaptive kernel, sub-county estimation method aggregated observed and expected counts of cervical cancers into larger, homogeneous geographic units that included a minimum of 5,000 females older than age 20 years. This spatial smoothing method ensured adequate sample size for mapped homogeneous geographic units. GIS functions were used to create six ordinal categories for cervical cancer IRs, which were then mapped [33,34]

We utilized a three-step process to formally evaluate spatial clustering in the geographic distribution of cervical cancer [30]. The first step involved calculating cervical cancer IRs for each collection of eight nearest neighbor BGs using a spatial weights matrix [35]. In step two, the global Moran’s I coefficient was used to assess global spatial auto correlation between each BG, with the closest eight BG neighbors [36]. Step three involved calculating local indicators of spatial association (LISA) [37] to identify clusters of BGs exhibiting IR values that differed significantly from statewide average values. False Discovery Rate (FDR) [38] procedures were used to correct for multiple testing and spatial dependency [39] when reporting statistical significance findings.

A choropleth map of California was constructed depicting the geographic distribution of SES quintile levels measured for Year 2010 Census BGs ((Figure 2) Map A). The cross-LISA index measuring cross-correlation between two standardized spatial variables [40] was computed and plotted using Geo DA software (version 1.0.1) [41]. This index identified geographic areas depicting unique local associations between continuous IR and SES matrix levels. County borders were shown on each map to provide geographic reference.


During 2006-2011, 8,413 California residents were diagnosed with cervical cancer. Among these, 337 (4.0%) consisted of nonspecific cervical cancer types, 18(0.2%) were some form of basal cell carcinoma and 106 (1.3%) sarcomas and were excluded from study. In addition to these data for non-epidermoid carcinomas and non-adeno carcinomas, subjects missing information for age (n=179 [2.1%]), cases less than age 20 years at diagnosis (n=301 [3.6%]), cases that could not be geo coded to the BG level (n=57 [0.7%]) and 183 (2.2%) cases located in BGs having fewer than five counts were excluded from analysis. Data for the remaining 7,232 eligible study subjects were geo coded to the 5,933 California census block groups having at least one cervical cancer case diagnosed during the six-year study period

Table (1) presents the distribution of cervical cancers and BG counts according to each of six ordinal IR categories used to classify spatially smoothed data. Among the 7,232 California women diagnosed with cervical cancer, 1,642 (23%) occurred in areas having IR values ranging from greater than 1.25 to 4.77 (the three highest IR categories) at diagnosis. Data in Table 1 showed that 1,260 (21.2%) of the 5,933 California Year 2000 Census BGs having at least one cervical cancer case, were classified in the three highest IR categories. Table 2 presents counts and percentages of total cervical cancer cases and BG categories, according to SES quintiles. These findings indicate that 48 percent of cervical cancer cases occurred in the two lowest SES categories, representing 47 percent of the California census BGs with cervical cancers 

Figure (1) presents a reference map of California depicting county names and boundaries ((Figure 1) Map A), a spatially smoothed, hierarchal map of cervical cancer incident ratio categories ((Figure 1) Map B) and a map of LISAIR clusters assessed according to statistical criterion(p < 0.01) (Figure (1) Map C) [44]. This descriptive map of spatially smoothed ratios reflects differences in sub-areas of the 58 California counties ((Figure 1) Map B)with the highest cervical cancer IR levels occurring in eastern San Diego, central Imperial, south central San Bernardino, west central Los Angeles, western Ventura, central Kern, central Kings, south Tulare, central Fresno, eastern Merced and north western Madera counties. Northern California counties that showed highest IR values include Humboldt and Siskiyou Counties ((Figure 1). Map B). Moran’s I [36], a global spatial autocorrelation test, identified a tendency for clustering of cervical cancer IRs within adjacent census BGs (Moran’s I =0.738; p <0.001). Results for the local version of Moran’s I, LISA findings [44] revealed clusters of cervical cancer in areas of eastern Imperial and San Diego counties, desert areas of western San Bernardino County, central Kern and sporadic areas of Los Angeles counties. Additional areas of higher than average IR clusters were evident in Tulare, Kings, Fresno, south Monterey, Madera, Mariposa, Merced, Tuolumne, Butte, Lake, Mendocino, Trinity, Humboldt and Siskiyou Counties ((Figure 1) Map C).

(Figure2) presents a map depicting SES quintile levels in California ((Figure 2) Map A) and a map depicting significant BG clustering (p < 0.01) for cross-correlations between IR and SES measures for each BG cluster [35] computed using a crosscorrelation coefficient [40]. The geographic distribution of SES quintiles in California shows that the highest levels (depicted in blue) are predominantly located along the California coastline from Sonoma County southward, extending inland along the Interstate 80 corridor from the San Francisco to Sacramento and to mountain areas of eastern Placer and Eldorado counties. In southern California, high SES areas were also identified in coastal regions of Los Angeles, Orange, and San Diego Counties. Areas depicting the lowest SES quintile levels (red) include broad areas of eastern San Bernardino, Riverside and Imperial counties and wide areas of the California central valley that encompass parts of Kings, Kern and Fresno counties. Far northern California counties that depict large areas classified in the lowest SES quintile include northern Trinity, north central and southeastern Humboldt, north central Modoc and north eastern and northwestern Siski you counties ((Figure2) Map A).

Figure (2B) presents a map of the cross-correlation between statistical IR clusters and SES levels, based on the cross-correlation (LISA) index, depicting the degree to which cervical cancer IRs for a particular BG is related to the SES score for the neighboring eight BGs. Low SES and high IR areas (red) are evident in eastern Imperial, north eastern San Diego, wide areas of San Bernardino Counties, eastern Kern, south-central Los Angeles, Tulare, most of Kings, areas of Fresno, an east to west band through central Monterey, much of Madera, western Merced and along the state highway 99 and Interstate 5 corridors through Stanislaus, San Joaquin and Sacramento counties. Areas of low SES and high IR in the far northern part of California include parts of Glenn, Lake, Tehama, eastern Mendocino, southern Trinity, northern Humboldt and areas of Siskiyou and Modoc counties. There were other locations (displayed in blue) where the SES versus IR correlation also followed the expected direction of high SES and low IR. Figure (2C) presents a cross-correlation scatter plot, representing the cross-correlation between the two standardized spatial variables across BGs (I = -0.287; p <0.001)

Table 1: Counts (n) and percentages (%) of cervical cancer cases and block groups by incident ratio (IR) categories.
  Cancer Cases Census Block Group
IR Categories n % n %
0-0.50 1 0.01% 1 0.02%
>0.50-1.00 2,697 37.29% 2,323 39.15%
>1.00-1.25 2,892 39.99% 2,349 39.59%
>1.25-1.50 1,342 18.56% 1,038 17.50%
>1.50-2.00 272 3.76% 214 3.61%
> 2.00-4.77 28 0.39% 8 0.13%
Total 7,232 100.0% 5,933 100.0%
  Cancer Cases Census Block Group
SES Categories n % n %
1 1,890 26.13% 1,495 25.20%
2 1,586 21.93% 1,294 21.81%
3 1,440 19.91% 1,176 19.82%
4 1,286 17.78% 1,083 18.25%
5 (highest) 1,030 14.24% 885 14.92%
Total 7,232 100.0% 5,933 100.0%



In 2000, California ranked number two for cervical cancer incidence rates in the U.S. [3]. Every cervical cancer case representing failure of early detection (screening) [7] and treatment of premalignant dysplasia [45] and early-stage disease [7,45], identifying the tragedy of this ranking. In previous analyses, researchers identified roles for age, race/ethnicity, SES and marital status as predictors of late-stage cervical cancer diagnosis in California [16,19,46-49], while findings reported here identify geographic location in California depicting elevated cervical cancer incident ratios and case clustering.

Other investigators found that U.S. counties having low screening rates, tend to have higher cervical cancer incidence rates [50-52], more advanced stage diagnosis [50,51,53] and higher than average mortality rates [6,50]. While these findings reveal unique patterns of cervical cancer incidence, stage at diagnosis and risk of death at county levels, the large size and lack of demographic homogeneity for county geographic units in California, limit the value of these earlier findings for targeted cancer control and prevention programs.

Using census BGs, rather than counties, this investigation utilized Local Moran’s I, a measure of geographic correlation, to collapse neighboring BGs having similar cervical cancer IR levels,revealing clustering at sub-county levels. While our findings of significant geographic patterns in occurrence of cervical cancer are like those reported at county levels in the U.S. [50-52], use of sub-county geographic units depicting homogeneously higher than average cervical cancer IRs provides opportunity for application of focused control and prevention strategies

In contrast with previous studies, this current investigation identified unique cervical cancer incidence and socioeconomic status patterns measured at the census BG level; the smallest economically homogeneous census unit having cancer occurrence and SES data available. Incorporation of robust GIS analytic techniques, together with population-based California Cancer Registry data revealed patterns of unique cervical cancer occurrence in geographic units that can be targeted for cancer control.

Previous studies showed patterns for lower cervical cancer screening among residents of low SES counties [54], with a tendency for higher incidence rates measured for counties having low SES [55]. Findings reported here, provide map patterns depicting unique incident ratios, statistical LISA-derived IR clusters, SES quintiles and geographic areas depicting uniquely high or low Moran’s I values for spatial correlations between LISA IR cluster and SES values. This general relationship of moderate, negative cross-correlation Figure (2C) presents a cross-correlation scatter plot and suggests spatial correlations between cervical cancer and lower SES quintiles in California.

Sub-county geographic areas depicting unique high LISAderived IRs clusters, statistically elevated IR clusters and correlations between IR clusters and SES are identified in these results. Although these findings are consistent with countylevel evidence reported by other investigators [22,50,51,55], they extend this evidence by revealing geographic associations between cervical cancer incidence rates and low SES at subcounty levels. Combining contemporary population-based cancer registry data for California with, Census 2010 denominators and advanced GIS statistical methods, these new findings provide an intuitive means of identifying sub-county areas of California that may benefit, disproportionately, from targeted intensifies cervical cytology screening in the foreseeable future.


Exclusions of cervical cancer cases not classified by cell morphology, missing age at diagnosis, not geo coded to the BG level and subjects in BG clusters having fewer than five cases (n=756) has potential to introduce systematic error in our findings. Nevertheless, data for 90.5% (7,232/7,988) of the eligible targeted study subjects were included in this study, minimizing the magnitude of differential bias resulting from missing data. Use of the multidimensional ecologic SES index relies on average SES scores computed for census BGs of residence that will differ from individual SES measures for some individuals. Nevertheless, the multidimensional character of the CCR SES index includes a principal component derived composite of seven community SES dimensions that arguably provides better portrayal of Pap screening barriers than a single component SES measure in individuals. Details regarding derivation and validation of the CCR SES index are available from the Cancer Prevention Institute of California [28]. Methods used to form the adaptive kernel and LISA cluster population (geographic) units rely on weighted averages of census BG measures when forming BG clusters. While this approach is expected to enhance specificity for identifying uniquely high and low geographic IR patterns, averaging disparate results for adjacent BGs contained within clusters tends to reduce sensitivity for identifying uniquely high or low effects. This potential loss of sensitivity and enhancement of specificity, likely concealed some small and isolated IR clusters, yielding fewer false positives for the presence of uniquely high or low IR findings, increasing false negatives (Figure 1 B,C). Although it seems reasonable to presume that low SES might contribute to elevated IR levels in sub-county areas assessed, the crosssectional character of the SES and IR measures used in this study precludes determination of the temporal association between these characteristics. Findings from this study are unique to California, a state having counties that exceed the population size, geographic areas and demographic diversity of some US states and having distinctive geographic features that include the pacific coastline, a southern international border, mountain ranges and large, sparsely populated desert regions.


Cervical cancer is detectable during a treatable stage through Pap testing and preventable through HPV vaccination, with inequitable distribution of prevention resources predicted by geography and SES. Findings presented here depict cervical cancer incident ratios and statistical patterns that reveal sub-county areas of California exhibiting higher than average occurrence of cervical cancer for 2006-2011. This inequity is predicted by lower than average SES in some geographic areas of California. Assuming that circumstances predicting the geographic patterns revealed in this study persist to today, it is reasonable to infer that this information could be used to diminish the occurrence of future cervical cancer cases in California. Combined with local understanding of underserved population characteristics, this information could be used to target high risk segments of the California population through strategic placement of culturally and language sensitive health education and screening resources. Among these strategies, increased utilization of HPV vaccination [12] and Pap screening [56,57], according to current public health recommendations, targeted to sub-county geographic areas having higher than average IRs and in areas showing statistical clustering of cervical cancers cases, could be used to minimize risk for this preventable disease. It is our belief that incorporating these findings as part of current and planned cervical cancer prevention programs will enhance the success of those programs.


All authors have participated in (a) conception and design, or analysis and interpretation of the data; (b) drafting the article or revising it critically for important intellectual content; and (c) approval of the final version.

The authors have no affiliation with any organization with a direct or indirect financial interest in the subject matter discussed in the manuscript.


1. American Cancer Society, What Are the Key Statistics About Cervical Cancer? Information.

2. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society. 2014.

3. US Cancer Statistics Working Group (2009) United States cancer statistics: 1999–2010 incidence and mortality web-based report. US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute.

4. California Cancer Registry. Data Mapping & Tools 2006-2011. http:// www.cancer-rates.info/ca/index.php. Accessed Date April 23, 2015. Based on October 2013 Extract Released December 13, 2013.

5. Fisher JW, Brundage SI. The Challenge of Eliminating Cervical Cancer in the United States: A Story of Politics, Prudishness, and Prevention, Women & Health. 2009; 49: 246-261.

6. Nelson W, Moser RP, Gaffey A, Waldron W. Adherence to cervical cancer screening guidelines for U.S. women aged 25–64: Data from the 2005 health information national trends survey (HINTS). J Womens Health. 2009; 18: 1759-1768.

7.  Austin RM, Zhao C. Type 1 and type 2 cervical carcinomas: some cervical cancers are more difficult to prevent with screening. Cytopathology. 2012; 23: 6-12.

8. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, BultenJ. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008; 111: 167- 177.

9. Cancer Program Standards 2012: Ensuring Patient-Centered Care. American College of Surgeons Commission on Cancer. 2011.

10. Howlader N, NooneAM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2010, and National Cancer Institute. Bethesda, MD, based on November 2012 SEER data submission, posted to the SEER web site. 2013.

11. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.

12. Centers for Disease Control and Prevention (CDC). Epidemiology and Prevention of Vaccine-Preventable Diseases The Pink Book: Course Textbook-12th Edition Second Printing (May 2012)”. Human Papillomavirus.

13. Karanam B, Jagu S, Huh WK, Roden RB. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 2009; 87: 287-299.

14. Wilyman J. HPV vaccination programs have not been shown to be costeffective in countries with comprehensive Pap screening and surgery. Infect Agent Cancer. 2013; 8: 21.

15. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. InternationalAgency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98: 303-315.

16. Eggleston KS, Coker AL, Williams M, Tortolero-Luna G, Martin JB, Tortolero SR. Cervical cancer survival by socioeconomic status, race/ ethnicity, and place of residence in Texas 1995-2001. J Womens Health (Larchmt). 2006; 15: 941-951.

17. McCarthy AM, Dumanovsky T, Visvanathan K, Kahn AR, Schymura MJ. Racial/ethnic and socioeconomic disparities in mortality among women diagnosed with cervical cancer in New York City, 1995-2006. Cancer Causes Control. 2010; 21: 1645-1655.

18. Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004; 101: 1051- 1057.

19. Saghari S, Ghamsary M, Marie-Mitchell A, Oda K, Morgan JW. Sociodemographic predictors of delayed- versus early-stage cervical cancer in California. Ann Epidemiol. 2015; 25: 250-255.

20. Coughlin SS, King J, Richards TB, Ekwueme DU. Cervical cancer screening among women in metropolitan areas of the United States by individual-level and area-based measures of socioeconomic status, 2000 to 2002. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2154– 2159.

21. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003; 97: 1528-1540.

22. Holt JB. The topography of poverty in the United States: a spatial analysis using county-level data from the Com-munity Health Status Indicators project.Prev Chronic Dis. 2007; 4: 111.

23. Freeman HP, Wingrove BK, editors. Excess cervical cancer mortality: a marker for low access to health care in poor communities. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities. 2005

24. Lengerich EJ, Tucker TC, Powell RK, Colsher P, Lehman E, Ward AJ, et al. Cancer incidence in Kentucky, Pennsylvania, and West Virginia: disparities in Appalachia. J Rural Health. 2005; 21: 39–47.

25. Horner MJ, Altekruse SF, Zou Z. U.S geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol Biomarkers Prev. 2011; 20: 591–599

26. Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, et al. Burden of cervical cancer in the United States, 1998–2003. Cancer. 2008; 113: 2855-2864

27. Liu L, Deapen D, Bernstein L. Socioeconomic status and cancers of the female breast and reproductive organs: a comparison across racial/ ethnic populations in Los Angeles County, California (United States). Cancer Causes Control. 1998; 9: 369-380.

28. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001; 12: 703-711.

29. Yang J, Schupp CW, Harrati A, Clarke C, Keegan THM, Gomez SL. Developing an area-based socioeconomic measure from American Community Survey data. Cancer Prevention Institute of California, Fremont, California. 2014.

30. SAS; SAS Institute, Cary, NC) (SAS [computer program].Version 9.3. Cary, NC: SAS Institute; 2008.

31. Environmental Systems Research Institute. ArcMap: Version 10.3. Redlands (CA): ESRI; 2014.

32. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin M, Whelan S, eds. International Classification of Diseases for Oncology. 3rd ed.Geneva: World Health Organization; 2000.

33. Szklo M, Nieto F. Javier. Epidemiology Beyond the Basics. 2000; Aspen Publishers, Inc, Gaithersburg, Maryland.

34. Talbot TO, Kulldorff M, Forand SP, Haley VB. Evaluation of spatial filters to create smoothed maps of health data. Statistics in Medicine. 2000; 19: 2399-2408.

35. Will JC, Nwaise IA, Schieb L, ZhongY. Geographic and racial patterns of preventable hospitalizations for hypertension: Medicare beneficiaries, 2004-2009. Publich health report. 2014; 129: 8-18.

36. Moran PA. Notes on continuous stochastic phenomena. Biometrika. 1950; 37:17-23.

37. Anselin L. Local Indicators of Spatial Association-LISA. Geographical Analysis. 1995; 27: 93-115.

38. Caldas de Castro M, Singer BH. Controlling the False Discovery Rate: A New Application to Account for Multiple and Dependent Test in Local Statistics of Spatial Association. Geographical Analysis. 2006; 38: 180- 208.

39. Wartenberg D. Multivariate spatial correlation: A method for exploratory geographical analysis. Geographical Analysis. 1985; 17: 263-283.

40. GeoDa Center for Geospatial Analysis and Computation. GeoDA. Tempe (AZ): GeoDa Center for Geospatial Analysis and Computation: 2012.

41. Talbot TO, Kulldorff M, Forand SP, Haley VB. Evaluation of spatial filters to create smoothed maps of health data. Stat Med. 2000; 19: 2399-2408.

42. Anselin L. Local Indicators of Spatial Association-LISA. Geographical Analysis. 1995; 27: 93-115.

43. Garner EI. Cervical cancer: disparities in screening, treatment, and survival. Cancer Epidemiol Biomarkers Prev. 2003; 12: 242-247.

44. Dinkelspiel H, Fetterman B, Poitras N, Kinney W, Cox JT, Lorey T, et al. Screening history preceding a diagnosis of cervical cancer in women age 65 and older. Gynecol Oncol. 2012; 126: 203-206.

45. Kamineni A, Weinmann S, Shy KK, Glass AG, Weiss NS. Efficacy of screening in preventing cervical cancer among older women. Cancer Causes Control. 2013; 24: 1653-1660.

46. Ferrante JM, Gonzalez EC, Roetzheim RG, Pal N, Woodard L. Clinical and demographic predictors of late-stage cervical cancer. Arch Fam Med. 2000; 9: 439-445.

47. Goodwin JS, Hunt WC, Key CR, Samet JM. The effect of marital status on stage, treatment, and survival of cancer patients. JAMA. 1987; 258: 3125-2130.

48. Horner MJ, Altekruse SF, Zou Z, Wideroff L, Katki HA, Stinchcomb DG. U.S. geographic distribution of pre vaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol Biomarkers Prev. 2011; 20: 591–599.

49. Coughlin SS, Richards TB, Nasseri K, Weiss NS, Wiggins CL, Saraiya M, et al. Cervical cancer incidence in the United States in the US-Mexico border region. 1998-2003. Cancer. 2008; 113: 2964–2973.

50. Niccolai L, Julian PJ, Bilinski A, Mehta NR, Meek J, Zelteman D, et al. Geographic Poverty Racial/Ethnic Disparities in Cervical Cancer Precursor Rates in Connecticut, 2008-2009. Am J Public Health. January 2013; 103: 156-163.

51. Lengerich EJ, Tucker TC, Powell RK, Colsher P, Lehman E, Ward AJ, et al. Cancer incidence in Kentucky, Pennsylvania, and West Virginia: disparities in Appalachia. J Rural Health. 2005; 21: 39–47.

52. Wallace D, Hunter J, Papenfuss M, de Zapien JG, Denman C, Giuliano AR. Pap smear screening among women > 40 years residing at the United States-Mexico border. Health Care Women Int. 2007; 28: 799- 816.

53. Hofer BM, Bates JH, McCusker ME, Nasseri K, Cress RD, Snipes KP. Cervical Cancer in California, 2008. Sacramento, CA: California Department of Public Health, Cancer Surveillance Section, January 2008.

54. U.S. Preventive Services Task Force. Recommendations and Rationale: Screening for Cervical cancer. USPSTF. 2000.

55. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. CA Cancer J Clin. 2002; 52: 8-22.


 Saghari S, Soret S, Ghamsary M, Santos E, Marie-Mitchell A, et al. (2016) Geographic Distribution of Cervical Cancer in California: A Population Based Study. JSM Women’s Health 1(1): 1001.


Introduction: Cervical cancer, a screen-preventable disease, is expected to result in 4,100 deaths in the US during 2015.Previous researchers have reported variation in incidence and mortality rates for cervical cancer in the US, although, the large size of many California counties restricts the utility of county-specific findings for some targeted control and prevention strategies. Other studies have identified associations between low socioeconomic status (SES) and increased occurrence of cervical cancer or delayed-stage diagnosis.

Objectives: This research sought to use epidemiologic and geographic information systems methods and California Cancer Registry data to assess whether cervix cancer cases in California distribute randomly and to map sub-county occurrence of cervical cancer. An additional objective included assessment of the association between sub-county areas exhibiting lower than average SES and occurrence of cervical cancer. 

Methods: This population-based, cross-sectional study evaluated and mapped ordinal, sub-county, categories of incident ratios (IR) representing observed versus expected counts of cervical cancers diagnosed among California women older than age 20 years for 2006-2011. Other sub-county area maps of California assessed statistical clustering of cervical cancers, areas showing unique SES patterns and cross-correlations between cervical cancer IRs and SES. 

Results: Global assessment revealed non-random patterns in sub-county IRs (p < 0.001). Unique IR levels and statistical IR clusters are evident in southern desert, central valley, far northern and other sub-county areas of California. Other maps identify sub-county areas of California depicting unique SES levels and a significant spatial cross-correlation between areas experiencing high IRs and low SES.

Conclusion: These sub-county findings depict geographic areas of California that experienced higher than average observed counts of cervical cancer that could be targeted for intensified screening. The significant cross-correlation between areas depicting high IRs and low SES reveal sub-county patterns in which ecologic measures of SES predicted IR clusters.

Received : 18 Aug 2016
Accepted : 18 Oct 2016
Published : 20 Oct 2016
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
TEST Journal of Dentistry
ISSN : 1234-5678
Launched : 2014
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X